Jack Silberstein
Chief Executive Officer & Founder Deck Bio
Jack aims to engineer a designer immune checkpoint inhibitor with significantly enhanced binding affinity for specific immune inhibitory ligands as a way of blocking inhibitory signaling in T cells. With this targeted approach, Jack hopes to more effectively block cancer’s immunosuppression, thereby maximizing the therapeutic potential of immune checkpoint blockade.
Seminars
Tuesday 23rd June 2026
Synchronizing Global Regulatory Strategies through Modelling & Translational Approaches for Next-Generation TCEs
2:00 pm
Join this workshop to explore how mechanistic modelling, in vitro systems, and translational data can be used to address non-clinical gaps and support a shift from animal-heavy approaches toward predictive, weight-of-evidence frameworks.
- Identifying scientific inconsistencies across current non-clinical approaches, with a focus on the role and limitations of non-human primate data
- Applying PK/PD and systems-level modelling to support weight-of-evidence frameworks, clarify risk, and inform non-clinical decision-making
- Leveraging existing clinical and marketed product data, supported by comparative modelling, to strengthen confidence in new molecules
- Aligning modelling and translational strategies with differing global regulatory expectations to enable more consistent and efficient development pathways across regions
- Exploring how sponsors can proactively engage regulators with modelling-supported non-clinical packages to align on expectations early and avoid late-stage study requests
Wednesday 24th June 2026
Panel Discussion: Translating Mechanistic Insights into Effector Durability through Mitigating T-Cell Exhaustion
2:30 pm
- Analyzing whether mass changes in peripheral T-cell capacity serve as a predictive biomarker for clinical response are a signature of therapeutic failure
- Identifying points where TCEs fail to maintain sustained cytotoxic pressure and harnessing these insights to inform the timing of TCE administration
- Understanding how chronic antigen exposure under TCE stimulation drives effector dysfunction and how these findings can be used to engineer more resilient T-cell therapies
Wednesday 24th June 2026
Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting
1:30 pm
- Addressing the fundamental challenge of low pMHC copy number and target heterogeneity that limits TCE efficacy in solid tumors through multi-pMHC recognition strategies
- Demonstrating how engineered TCRs can recognize multiple cancer-restricted pMHCs through shared structural motifs, enabling potent T cell activation at sub-10 pM EC50s while maintaining specificity
- Establishing comprehensive specificity de-risking approaches using sequence-agnostic, immunopeptidomics-based screening across >13,000 healthy tissue peptides to support broad application across major solid tumor indications
